Tirzepatide side effects: the real risk profile, by trial data

Last updated 2026-07-27

What are the most common tirzepatide side effects?

Nausea, diarrhea, vomiting, constipation, and stomach pain. That's the list, in roughly that order of frequency. These are the same GI effects seen across the entire GLP-1/GIP class, and they're dose-dependent: they get worse as you go from 2.5 mg up to 15 mg. In the SURMOUNT-1 trial (obesity/overweight without diabetes, NCT04184622), nausea occurred in about 24-33% of people on tirzepatide depending on dose, versus roughly 10% on placebo ^[1]. Diarrhea ran 15-21%, and vomiting 8-13% ^[1]. Most of these were described as mild to moderate, and the trial's published results noted that GI adverse events were "dose-dependent and mostly mild-to-moderate in severity, occurring primarily during dose escalation" ^[1]. In SURPASS-2 (type 2 diabetes, tirzepatide vs. semaglutide 1 mg, NCT03987919), nausea occurred in about 17-22% of tirzepatide arms and 18% on semaglutide; diarrhea ran 13-16% across tirzepatide doses ^[2]. So the GI burden is comparable to, maybe slightly higher than, high-dose semaglutide, but not wildly different. The practical pattern: symptoms cluster around each dose increase and usually calm down within 1-2 weeks at a stable dose. That's the whole logic behind slow titration schedules. If you're adjusting doses on your own, our Tirz Rx dosage guide and the dosage calculator walk through standard step-ups so you're not jumping too fast.

How common is nausea and vomiting on tirzepatide, exactly?

Nausea is the single most common side effect, affecting roughly one in four to one in three users depending on dose and study. It's worse at 15 mg than at 5 mg, and worse in the first 4-8 weeks than later. Across SURMOUNT-1's 72-week data, nausea rates by arm were approximately 24% (5 mg), 33% (10 mg), and 31% (15 mg), compared to 10% on placebo ^[1]. Vomiting followed a similar dose-response curve, landing around 8-13% on active drug versus roughly 2% on placebo ^[1]. Vomiting that's severe enough to cause dehydration is uncommon but not zero, and it's the reason prescribing information recommends caution in people with reduced fluid intake, since dehydration can worsen kidney function in people already at risk ^[3]. If you're vomiting repeatedly and can't keep fluids down, that's a call-your-prescriber situation, not a wait-it-out situation. A practical note that helps a lot of people: nausea is worse with fatty, heavy meals and large portions. Smaller, lower-fat meals eaten slowly cut down on symptoms for a lot of users, though that's practical advice, not a clinical finding from the trials themselves.

Can tirzepatide cause pancreatitis?

Yes. Pancreatitis has been reported in people taking tirzepatide, though it's uncommon. The prescribing information for both Zepbound and Mounjaro carries a warning about acute pancreatitis, and the label states that tirzepatide "has not been studied in patients with a history of pancreatitis" and should be discontinued if pancreatitis is suspected ^[3]. In the SURMOUNT and SURPASS trial programs, pancreatitis cases were rare, in the range of well under 1% of participants, but they occurred more often on tirzepatide than on placebo or comparator in some analyses. This mirrors what's been seen with GLP-1 drugs generally: the signal is real but small, and it's one reason a history of pancreatitis is something you need to disclose before starting. Symptoms to know: severe, persistent abdominal pain that may radiate to the back, sometimes with nausea and vomiting that's different from the usual GI side effects. That combination warrants urgent medical evaluation, not a wait-and-see approach.

Does tirzepatide cause gallbladder problems?

Gallbladder disease, including gallstones (cholelithiasis) and inflammation (cholecystitis), showed up more often in tirzepatide trial participants than in those on placebo. This is a known class effect tied to rapid, substantial weight loss, not something unique to tirzepatide's mechanism. In SURMOUNT-1, cholelithiasis was reported in about 1.6% of people on tirzepatide across doses, compared to roughly 0.5% on placebo ^[1]. That's a small absolute number, but it's a consistent enough pattern that FDA labeling flags gallbladder-related adverse reactions ^[3]. The mechanism isn't mysterious: losing weight fast, especially more than about 1.5 kg (3 lb) per week sustained over months, increases cholesterol saturation in bile and raises gallstone risk. This isn't unique to GLP-1/GIP drugs, it's the same reason bariatric surgery and very-low-calorie diets carry the same warning. Symptoms to watch for: pain in the upper right abdomen, especially after fatty meals, sometimes with fever or yellowing of the skin or eyes (jaundice). Gallbladder pain that's new and doesn't fit your usual GI side effects deserves a call to your prescriber, and jaundice or fever alongside abdominal pain is an urgent, same-day issue.

What is the thyroid cancer warning on tirzepatide, and how worried should I be?

Both Zepbound and Mounjaro carry a boxed warning, the FDA's strongest label warning, about thyroid C-cell tumors. This comes from rodent studies, not confirmed human cases, but the mechanism (GLP-1 receptor activation in thyroid C-cells) is shared across the drug class, so FDA applies the warning broadly. The label states tirzepatide "causes thyroid C-cell tumors in rats" and that it's "unknown whether Zepbound/Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans" ^[3]. Because that human risk can't be ruled out, the drug is contraindicated in anyone with a personal or family history of MTC and in people with Multiple Endocrine Neoplasia syndrome type 2 (MEN2) ^[3]. This is a real, hard contraindication, not a soft caution. If you or a close family member has had medullary thyroid cancer, or you have MEN2, tirzepatide is not an option, full stop, regardless of source (branded or compounded). For everyone else, the practical read: rodent thyroid tumor findings with this drug class have not translated into a confirmed signal in the large human trials or in over a decade of GLP-1 postmarketing data, but FDA and prescribers still watch for it. Report any new neck lump, hoarseness, difficulty swallowing, or shortness of breath to your prescriber promptly.

Are there other serious risks: kidney injury, allergic reactions, low blood sugar?

Acute kidney injury has been reported, usually as a downstream effect of severe vomiting or diarrhea causing dehydration, not as a direct toxic effect of the drug itself. The label notes tirzepatide can worsen renal function in patients experiencing significant GI adverse reactions, and recommends monitoring kidney function in people who develop severe GI symptoms ^[3]. Hypersensitivity reactions, including anaphylaxis and angioedema, have been reported in postmarketing data, and the label advises discontinuing the drug immediately if a serious hypersensitivity reaction is suspected ^[3]. This is uncommon but not zero, and it's why the first dose is worth taking somewhere you can watch for a reaction, even though it doesn't need to be in a clinic. Hypoglycemia (low blood sugar) is a real risk, but mainly when tirzepatide is combined with insulin or a sulfonylurea. In SURPASS-2, severe or documented hypoglycemia occurred in a small percentage of participants on tirzepatide alone, but rates rose meaningfully when it was combined with sulfonylureas ^[2]. If you're on insulin or a sulfonylurea and starting tirzepatide, your prescriber should be adjusting those other medication doses alongside the titration, not leaving them static. Injection site reactions (redness, itching, small welts) happen but are generally mild and don't require stopping treatment. Rotating injection sites and using correct injection technique cuts down on these.

Does tirzepatide cause hair loss?

Hair thinning has been reported by tirzepatide users, but it's not listed as a common adverse event in the SURMOUNT or SURPASS trial data at rates clearly above placebo. What's more likely happening: rapid, significant weight loss itself, from any cause, can trigger telogen effluvium, a temporary shedding phase that shows up 2-4 months after a metabolic stressor and typically resolves on its own within 6-9 months. This pattern was documented decades before GLP-1 drugs existed, in people after bariatric surgery, crash diets, and even severe illness or fever. It's a weight-loss-associated phenomenon, not a specific tirzepatide toxicity, and it's not mentioned as a distinct adverse reaction category in the FDA label ^[3]. If hair loss happens, it's usually not permanent. Ensuring adequate protein and overall nutrition during a rapid weight loss phase is the standard, sensible mitigation, though there's no dedicated trial data proving it prevents shedding tied to tirzepatide specifically.

How do side effects differ between Mounjaro, Zepbound, and compounded tirzepatide?

Mounjaro and Zepbound are the same active molecule at the same FDA-approved doses (2.5 mg through 15 mg), just marketed for different indications: Mounjaro for type 2 diabetes, Zepbound for chronic weight management. Their side effect profiles, drawn from SURPASS and SURMOUNT respectively, are essentially the same drug's data, and both carry the identical boxed warning and contraindications ^[3]. Compounded tirzepatide is a different situation entirely. It's not FDA-approved, meaning it hasn't gone through the agency's premarket review for safety, efficacy, or manufacturing quality at the specific pharmacy producing it. FDA has published warnings about compounded semaglutide and tirzepatide products, including concerns about dosing errors, use of salt forms (like tirzepatide acetate or other salts) that have not been shown to be safe or effective, and contamination risks tied to inconsistent compounding practices ^[4]. That doesn't mean every compounded product is dangerous. Sterile compounding is a regulated pharmacy practice with its own USP quality standards. But it does mean the safety data you're relying on (SURPASS, SURMOUNT) was generated using the FDA-approved formulation, not necessarily whatever a given compounding pharmacy is producing. If you go the compounded route, sourcing from a facility with real quality controls, and getting the product provider-reviewed before you start, matters more than it does with a branded pen. Tirz Rx's provider-reviewed process exists for exactly this gap: matching you with a fulfilling pharmacy partner rather than skipping that oversight step. Dosing considerations differ too. Compounded products are sometimes sold in concentrations or vial sizes that don't map directly onto the branded pens, which is part of why accurate reconstitution and dosing math matter more, not less, when you're not using a pre-filled pen.

How long do tirzepatide side effects last, and do they get better over time?

For most people, GI side effects are worst in the first 4-8 weeks after starting or after each dose increase, then taper off substantially. This is why the FDA-approved titration schedule for both Zepbound and Mounjaro starts at 2.5 mg for 4 weeks (a non-effective 'starter' dose meant purely to build tolerance) before stepping up ^[3]. In SURMOUNT-1, discontinuation due to adverse events was around 4.3-7.1% across active-drug doses versus 2.6% on placebo, meaning the large majority of participants who experienced side effects stayed on treatment ^[1]. That's a reasonable proxy for what to expect: uncomfortable, often tolerable, occasionally bad enough to stop. Our cycle length guide covers how titration timing interacts with longer-term treatment planning, including why slower step-ups (staying at each dose 4-6 weeks instead of the minimum required) often reduce side effect severity for people who are especially sensitive to GI symptoms.

Who should not take tirzepatide? (contraindications)

Frequently asked questions

What percentage of people get nausea on tirzepatide?

In SURMOUNT-1, nausea occurred in about 24% of people on the 5 mg dose, 33% on 10 mg, and 31% on 15 mg, compared to roughly 10% on placebo, over 72 weeks ^[1]. It's the single most common side effect and tends to improve after the first few weeks at a stable dose.

Does tirzepatide cause hair loss?

Trial data doesn't show hair loss as a distinct, elevated adverse event, but users report thinning tied to rapid weight loss itself, a known pattern called telogen effluvium seen with any fast weight loss. It typically starts a few months in and resolves within 6-9 months without stopping treatment.

Is pancreatitis a real risk with tirzepatide?

Yes, though uncommon. FDA labeling warns that acute pancreatitis has been reported, and the drug hasn't been studied in people with a prior pancreatitis history ^[3]. Severe abdominal pain radiating to the back, especially with nausea and vomiting, needs urgent evaluation, not a wait-and-see approach.

What is the boxed warning on tirzepatide about?

Tirzepatide carries FDA's strongest warning label for thyroid C-cell tumors, based on rodent studies where the drug caused these tumors, with unknown human relevance ^[3]. It's contraindicated in anyone with personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

Can tirzepatide cause gallstones?

Yes. Cholelithiasis occurred in about 1.6% of SURMOUNT-1 participants on tirzepatide versus 0.5% on placebo ^[1]. This is tied to rapid weight loss generally, not a unique drug toxicity, and mirrors gallstone risk seen after bariatric surgery or very-low-calorie diets.

How is compounded tirzepatide's side effect profile different from Zepbound or Mounjaro?

The core molecule is the same, but compounded products aren't FDA-approved, so they haven't gone through the same premarket review. FDA has flagged concerns about dosing errors and unapproved salt forms in some compounded tirzepatide products ^[4]. Sourcing and formulation quality vary by pharmacy in ways branded pens don't.

How long do tirzepatide side effects last?

Most GI side effects peak in the first 4-8 weeks after starting or after a dose increase, then fade at a stable dose. Discontinuation due to side effects occurred in roughly 4-7% of trial participants across doses in SURMOUNT-1, meaning most people who had side effects stayed on treatment ^[1].

Can tirzepatide cause low blood sugar (hypoglycemia)?

On its own, tirzepatide carries a low hypoglycemia risk. Risk rises meaningfully when combined with insulin or sulfonylureas, per SURPASS-2 data ^[2]. If you're on either of those medications, your prescriber should adjust their doses when starting tirzepatide, not leave them unchanged.

Who should not take tirzepatide?

People with a personal or family history of medullary thyroid carcinoma, anyone with MEN2 syndrome, and those with known hypersensitivity to tirzepatide should not take it ^[3]. Caution applies with pancreatitis history, severe GI motility disorders, and pregnancy, which hasn't been studied in humans.

Are tirzepatide side effects worse than semaglutide's?

Roughly comparable, per head-to-head data. SURPASS-2 found nausea in 17-22% of tirzepatide arms versus 18% on semaglutide 1 mg, with diarrhea slightly higher on tirzepatide ^[2]. Neither drug has a dramatically cleaner GI side effect profile than the other at comparable doses.

Can tirzepatide cause an allergic reaction?

Yes, though it's uncommon. Postmarketing reports include hypersensitivity reactions such as angioedema and anaphylaxis, and the FDA label instructs discontinuing the drug immediately if a serious reaction is suspected ^[3]. Watch for swelling of the face or throat, difficulty breathing, or widespread hives after a dose.

Does tirzepatide cause kidney problems?

Direct kidney toxicity isn't the mechanism of concern; acute kidney injury reports are mostly linked to dehydration from severe vomiting or diarrhea. FDA labeling recommends monitoring kidney function in patients who develop significant GI side effects ^[3], particularly those with existing kidney impairment.

Sources

1. NEJM, SURMOUNT-1 trial results (Jastreboff et al., 2022): Tirzepatide GI adverse event rates and discontinuation rates by dose in adults with obesity/overweight, NCT04184622
2. NEJM, SURPASS-2 trial results (Frias et al., 2021): Head-to-head GI adverse event and hypoglycemia rates for tirzepatide vs. semaglutide 1 mg in type 2 diabetes, NCT03987919
3. FDA, Zepbound (tirzepatide) full prescribing information: Boxed warning on thyroid C-cell tumors, contraindications, pancreatitis, gallbladder disease, hypersensitivity, and renal impairment warnings
4. FDA, Medications containing semaglutide taken for type 2 diabetes or weight loss: FDA warnings on compounded GLP-1 drug products regarding dosing errors and unapproved salt forms
5. ClinicalTrials.gov, A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1): SURMOUNT-1 trial registration details, design, and dosing arms for tirzepatide in obesity/overweight participants